23.03.2011

Pharmaceutical firms sign licence agreement for Rescula eye drops

Pharmaceutical firms sign licence agreement for Rescula eye drops

Posted by Adrian Galbreth

Rescula eye drops are to be licensed across the world by Sucampo Pharmaceuticals Incorporated's wholly-owned subsidiary Sucampo Manufacturing & Research AG and R-Tech Ueno Ltd.

These eye drops contain the active pharmaceutical ingredient unoprostone isopropyl.

They are designed to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma and ocular hypertension who have proven to be intolerant of or unresponsive to other medicines that lower IOP.

Sucampo currently had the rights to license the eye drops in the US and Canada, but the new agreement means this will expand across the rest of the world, except for in Japan, Korea, Taiwan and China.

"We are very excited about this agreement, as we believe that unoprostone isopropyl has significant potential in several markets," said Dr Ryuji Ueno, chairman and chief executive officer at Sucampo Pharmaceuticals.

According to the NHS, about 480,000 people have chronic open-angle glaucoma in England and other forms of the condition are less common. 

by Emily Tait


« Back to list